Skip to main content
SpringerLink
Log in

Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W (2021) Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440–1453

    Article  CAS  Google Scholar 

  2. Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, D’Incalci M et al (2019) Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica 104(5):e222–e223

    Article  CAS  Google Scholar 

  3. Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW et al (2021) Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440–1453

    Article  CAS  Google Scholar 

  4. Zhang X, Chen J, Wang W, Li X, Tan Y, Zhang X et al (2021) Treatment of central nervous system relapse in acute promyelocytic leukemia by Venetoclax: a case report. Front Oncol 11:693670

    Article  Google Scholar 

  5. Dimou M, Bitsani A, Roumelioti M, Dimitrakopoulou A, Iliakis T, Pardalis V et al (2021) Richter’s transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease “sanctuary” during venetoclax treatment? Clin Case Rep 9(4):2249–2253

    Article  Google Scholar 

  6. Ram R, Amit O, Zuckerman T, Gurion R, Raanani P, Bar-On Y et al (2019) Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol 98(8):1927–1932

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by grants from the Young and Middle-Aged Science Foundation of Harbin Medical University (YKCX2018-15) and Horizontal Project of Technology Development of Harbin Institute of Technology (No. JH20180176).

Author information

Authors and Affiliations

  1. Harbin Medical University, Harbin, China

    Yanling Li

  2. Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    Haibin Dai, Dandan Yao, Xinyu Gao, Yanming Xue & Wei Wang

Authors
  1. Yanling Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haibin Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dandan Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinyu Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanming Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Wang.

Ethics declarations

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient for the treatment.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Dai, H., Yao, D. et al. Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission. Ann Hematol 101, 1865–1867 (2022). https://doi.org/10.1007/s00277-022-04823-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04823-w

Search

Navigation